Phase I, Open Label, Unicentric Study of Multiple-dose Pharmacokinetics of Raltegravir in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus With and Without Advanced (Child-Pugh C) Hepatic Cirrhosis.

Trial Profile

Phase I, Open Label, Unicentric Study of Multiple-dose Pharmacokinetics of Raltegravir in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus With and Without Advanced (Child-Pugh C) Hepatic Cirrhosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2013

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms LIVERAL
  • Most Recent Events

    • 07 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Planned number of patients changed to 10.
    • 11 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top